Cochlear’s newest active bone conduction sound processor features a fully rechargeable battery, expanded fitting range, a new signal processing chip, and multi-platform wireless streaming — with US availability expected in early fall 2026....
No immediate practice change required; clinicians fitting active bone conduction devices should note the Osia 3's expanded fitting range and wireless streaming capabilities for future candidacy counselling once the device reaches the US market in early fall 2026.
FDA clearance of the Osia 3 expands the active bone conduction implant market with a next-generation processor, potentially broadening the candidate pool and raising patient expectations for wireless connectivity and rechargeable power.
- 01FDA clearance granted for Cochlear's Osia 3 active bone conduction sound processor.
- 02Key upgrades include a rechargeable battery, a new signal processing chip, and multi-platform wireless streaming.
- 03Expanded fitting range may make more patients eligible for this device category.
- 04US commercial availability is targeted for early fall 2026.
- 05No independent clinical outcome data were provided alongside the clearance announcement.
The Osia 3 features a rechargeable battery.
press releasepromotionalThe Osia 3 has an expanded fitting range compared to its predecessor.
press releasepromotionalThe Osia 3 supports multi-platform wireless streaming.
press releasepromotionalThe Osia 3 received FDA clearance.
press releasesupportedUS availability of the Osia 3 is expected in early fall 2026.
press releaseunclear
